Opportunity ID: 290038
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HRSA-17-078 |
| Funding Opportunity Title: | Sickle Cell Disease Treatment Demonstration Regional Collaboratives Program |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=c6084989-3725-4b51-b309-206698402829 |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 93.365 — Sickle Cell Treatment Demonstration Program |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Nov 10, 2016 |
| Last Updated Date: | Jan 13, 2017 |
| Original Closing Date for Applications: | Jan 13, 2017 |
| Current Closing Date for Applications: | Feb 09, 2017 |
| Archive Date: | Feb 27, 2017 |
| Estimated Total Program Funding: | $3,575,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Eligible entities for this cooperative agreement program are any federally-qualified health center, nonprofit hospital or clinic, or university health center that provides primary health care that: (1) has a collaborative agreement with a community-based sickle cell disease organization or a nonprofit entity with experience in working with individuals with sickle cell disease; and (2) demonstrates that it, the collaborative entity, or the experts described in section 712(c)(2)(C) of the American Jobs Creation Act of 2004, has at least five (5) years of experience working with individuals who have sickle cell disease. Faith-based and community-based organizations that meet these qualifications are eligible to apply.
Foreign entities are not eligible for HRSA awards, unless the authorizing legislation specifically authorizes awards to foreign entities or the award is for research. This exception does not extend to research training awards or construction of research facilities. |
Additional Information
| Agency Name: | Health Resources and Services Administration |
| Description: | This announcement solicits applications for the Sickle Cell Treatment Demonstration Regional Collaboratives Program. The purpose of this funding opportunity is to fund Regional Coordinating Centers (RCC) that will establish regional networks and provide leadership and support for regional and statewide activities that will develop and establish systemic mechanisms to improve the prevention and treatment of Sickle Cell Disease, by: (1) increasing the number of providers treating individuals with sickle cell disease using the National Heart, Lung and Blood Institute (NHLBI) Evidence-Based Management of Sickle Cell Disease Expert Panel Report;[1] (2) using telementoring, telemedicine[2] and other provider support strategies to increase the number of providers administering evidence-based sickle cell care; and 3) developing and implementing strategies to improve access to quality care with emphasis on individual and family engagement/partnership, adolescent transitions to adult life, and care in a medical home.
[1] National Heart, Lung and Blood Institute (NHLBI) Evidence-Based Management of Sickle Cell Disease Expert Panel Report can be found online. A quick guide of the recommendations can be found at: http://www.nhlbi.nih.gov/sites/www.nhlbi.nih.gov/files/Evd-Bsd_SickleCellDis_Rep2014.pdf [2] According to the American Telemedicine Association, telemedicine is the use of medical information exchanged from one site to another via electronic communications to improve a patient’s clinical health status. Telemedicine includes a growing variety of applications and services using two-way video, email, smart phones, wireless tools and other forms of telecommunications technology. (http://www.americantelemed.org/main/about/telehealth-faqs- ) |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Department of Health and Human Services, Health Resources and Services Administration
eivy@hrsa.gov Email:eivy@hrsa.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| N/A | Jan 13, 2017 | |
| Jan 13, 2017 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HRSA-17-078 |
| Funding Opportunity Title: | Sickle Cell Disease Treatment Demonstration Regional Collaboratives Program |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=c6084989-3725-4b51-b309-206698402829 |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 93.365 — Sickle Cell Treatment Demonstration Program |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Nov 10, 2016 |
| Last Updated Date: | Jan 13, 2017 |
| Original Closing Date for Applications: | Jan 13, 2017 |
| Current Closing Date for Applications: | Feb 09, 2017 |
| Archive Date: | Feb 27, 2017 |
| Estimated Total Program Funding: | $3,575,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Eligible entities for this cooperative agreement program are any federally-qualified health center, nonprofit hospital or clinic, or university health center that provides primary health care that: (1) has a collaborative agreement with a community-based sickle cell disease organization or a nonprofit entity with experience in working with individuals with sickle cell disease; and (2) demonstrates that it, the collaborative entity, or the experts described in section 712(c)(2)(C) of the American Jobs Creation Act of 2004, has at least five (5) years of experience working with individuals who have sickle cell disease. Faith-based and community-based organizations that meet these qualifications are eligible to apply.
Foreign entities are not eligible for HRSA awards, unless the authorizing legislation specifically authorizes awards to foreign entities or the award is for research. This exception does not extend to research training awards or construction of research facilities. |
Additional Information
| Agency Name: | Health Resources and Services Administration |
| Description: | This announcement solicits applications for the Sickle Cell Treatment Demonstration Regional Collaboratives Program. The purpose of this funding opportunity is to fund Regional Coordinating Centers (RCC) that will establish regional networks and provide leadership and support for regional and statewide activities that will develop and establish systemic mechanisms to improve the prevention and treatment of Sickle Cell Disease, by: (1) increasing the number of providers treating individuals with sickle cell disease using the National Heart, Lung and Blood Institute (NHLBI) Evidence-Based Management of Sickle Cell Disease Expert Panel Report;[1] (2) using telementoring, telemedicine[2] and other provider support strategies to increase the number of providers administering evidence-based sickle cell care; and 3) developing and implementing strategies to improve access to quality care with emphasis on individual and family engagement/partnership, adolescent transitions to adult life, and care in a medical home.
[1] National Heart, Lung and Blood Institute (NHLBI) Evidence-Based Management of Sickle Cell Disease Expert Panel Report can be found online. A quick guide of the recommendations can be found at: http://www.nhlbi.nih.gov/sites/www.nhlbi.nih.gov/files/Evd-Bsd_SickleCellDis_Rep2014.pdf [2] According to the American Telemedicine Association, telemedicine is the use of medical information exchanged from one site to another via electronic communications to improve a patient’s clinical health status. Telemedicine includes a growing variety of applications and services using two-way video, email, smart phones, wireless tools and other forms of telecommunications technology. (http://www.americantelemed.org/main/about/telehealth-faqs- ) |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Department of Health and Human Services, Health Resources and Services Administration
eivy@hrsa.gov Email:eivy@hrsa.gov |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HRSA-17-078 |
| Funding Opportunity Title: | Sickle Cell Disease Treatment Demonstration Regional Collaboratives Program |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=c6084989-3725-4b51-b309-206698402829 |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 93.365 — Sickle Cell Treatment Demonstration Program |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jan 13, 2017 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Jan 13, 2017 |
| Archive Date: | Feb 27, 2017 |
| Estimated Total Program Funding: | $3,575,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Eligible entities for this cooperative agreement program are any federally-qualified health center, nonprofit hospital or clinic, or university health center that provides primary health care that: (1) has a collaborative agreement with a community-based sickle cell disease organization or a nonprofit entity with experience in working with individuals with sickle cell disease; and (2) demonstrates that it, the collaborative entity, or the experts described in section 712(c)(2)(C) of the American Jobs Creation Act of 2004, has at least five (5) years of experience working with individuals who have sickle cell disease. Faith-based and community-based organizations that meet these qualifications are eligible to apply.
Foreign entities are not eligible for HRSA awards, unless the authorizing legislation specifically authorizes awards to foreign entities or the award is for research. This exception does not extend to research training awards or construction of research facilities. |
Additional Information
| Agency Name: | Health Resources and Services Administration |
| Description: | This announcement solicits applications for the Sickle Cell Treatment Demonstration Regional Collaboratives Program. The purpose of this funding opportunity is to fund Regional Coordinating Centers (RCC) that will establish regional networks and provide leadership and support for regional and statewide activities that will develop and establish systemic mechanisms to improve the prevention and treatment of Sickle Cell Disease, by: (1) increasing the number of providers treating individuals with sickle cell disease using the National Heart, Lung and Blood Institute (NHLBI) Evidence-Based Management of Sickle Cell Disease Expert Panel Report;[1] (2) using telementoring, telemedicine[2] and other provider support strategies to increase the number of providers administering evidence-based sickle cell care; and 3) developing and implementing strategies to improve access to quality care with emphasis on individual and family engagement/partnership, adolescent transitions to adult life, and care in a medical home.
[1] National Heart, Lung and Blood Institute (NHLBI) Evidence-Based Management of Sickle Cell Disease Expert Panel Report can be found online. A quick guide of the recommendations can be found at: http://www.nhlbi.nih.gov/sites/www.nhlbi.nih.gov/files/Evd-Bsd_SickleCellDis_Rep2014.pdf [2] According to the American Telemedicine Association, telemedicine is the use of medical information exchanged from one site to another via electronic communications to improve a patient’s clinical health status. Telemedicine includes a growing variety of applications and services using two-way video, email, smart phones, wireless tools and other forms of telecommunications technology. (http://www.americantelemed.org/main/about/telehealth-faqs- ) |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Department of Health and Human Services, Health Resources and Services Administration
eivy@hrsa.gov Email:eivy@hrsa.gov |
Related Documents
Packages
| Agency Contact Information: | Department of Health and Human Services, Health Resources and Services Administration eivy@hrsa.gov Email: eivy@hrsa.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.365 | HRSA-17-078 | Sickle Cell Disease Treatment Demonstration Regional Collaboratives Program | PKG00229174 | Feb 09, 2017 | View |
Package 1
Mandatory forms
Share This Post, Choose Your Platform!
About the Author: osnqt
